tofacitinib,adalimumab,secukinumab,methotrexate
novartis,abbvie,pfizer
['tofacitinib', 'adalimumab', 'axspa', 'surpass', 'tofa']
clinical highlights to end #eular2023 by christian dejaco 1/n a new dual jaki/tyk for ra head to head ada vs sec in spa (surpass) lots of registries collectively refuting the cv risk of tof (korean, jak-pot) mtx in hand oa (again!) (in those with synovitis) 
Rheumatologist @NUSingapore @AIIMS_NewDelhi || Follow for #Rheum nuggets 🦴|| #MedEd || Mummy of 2 || Dreamer || Views my own 🇸🇬🇮🇳